Oxalipatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells

Publisher:
Springer
Publication Type:
Journal Article
Citation:
Cancer Chemotherapy and Pharmacology, 2006, 58 (2), pp. 256 - 265
Issue Date:
2006-01
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2005001250.pdf849.66 kB
Adobe PDF
cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the devlopment of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known about oxaplatin in SCLC and there are no reports of oxaliplatin resistant SCLC cell lines. Studies of drug resistance mainly focus on the cellular resistance mechanisms rather than how the cells develop resistance. This study examines the development of cisplatin and oxalipaltin resistance in H69 human SCLC cells in response to repeated treatment with clinically relevant doses of cisplatin or oxaliplatin for either 4 days or 2 h.
Please use this identifier to cite or link to this item: